drugset

drugset / Trial / NCT02502097

A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)

NCT02502097 ↗

Phase 2 Completed 51 enrolled Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

RandomizedCrossoverQuadruple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled, crossover, dose escalation study of gefapixant (AF-219) in participants with Idiopathic Pulmonary Fibrosis (IPF) with persistent cough.

Timeline

Start: 2015-08-26
Primary completion: 2016-07-01
Completion: 2016-07-14

Publications

Martinez FJ, Afzal AS, Smith JA, Ford AP, Li JJ, Li Y, Kitt MM; Chronic Cough in IPF Study Group. Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial. Pulm Ther. 2021 Dec;7(2):471-486. doi: 10.1007/s41030-021-00162-9. Epub 2021 Jun 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefapixant	Small molecule	50 mg	Oral
Subject	Gefapixant	Small molecule	150 mg	Oral

Indications